Low-dose bromocriptine therapy in severe Parkinson's disease

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson's disease is a progressive neurodegenerative disorder.
• Current treatments have limitations, necessitating exploration of new therapeutic options.

Purpose of the Study:

• To evaluate the effectiveness and safety of bromocriptine mesylate as an initial treatment for severe idiopathic Parkinson's disease.

Main Methods:

• A single-blind study involving 15 patients with severe Parkinson's disease (Hoehn and Yahr Stages 4-5).
• Gradually increasing doses of bromocriptine mesylate (Parlodel) were administered, starting at 1.25 mg/day up to 15 mg/day.
• Patients were not on levodopa or amantadine, with only trihexyphenidyl HCl (Artane) permitted as an adjunctive therapy.

Main Results:

• 14 out of 15 patients showed satisfactory response, with significant improvement (at least two stages on the Hoehn and Yahr Scale).
• Clinical improvement was observed within 48 hours of initiating treatment with 1.25 mg/day of bromocriptine.
• No serious adverse reactions were reported with the dose escalation regimen.

Conclusions:

• Low-dose bromocriptine mesylate demonstrates promising efficacy and safety as a first-line therapy for severe idiopathic Parkinson's disease.
• Early initiation of bromocriptine may lead to rapid symptomatic relief in Parkinson's patients.